BridgeBio (NASDAQ: BBIO) will present primary Phase 3 CALIBRATE results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology (ECE) in Prague.
Presentations include two oral talks (May 12), one poster (P72) and one ePoster (EP260); presenters include Filomena Cetani and Arun Mathew.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BBIO
-0.30%
-0.30%Session close to close
In the May 5 session, BBIO declined 0.30%, reflecting a mild negative market reaction.
This announcement highlights upcoming presentations of Phase 3 CALIBRATE primary results for encaler...
Analysis
This announcement highlights upcoming presentations of Phase 3 CALIBRATE primary results for encaleret in ADH1 and related disease insights at the 2026 ECE meeting. It follows earlier positive topline CALIBRATE data and other Phase 3 successes in BridgeBio’s rare disease portfolio. Investors may watch for detailed efficacy, safety, and quality-of-life analyses, as well as how external endocrinology experts receive the data and what management signals about next regulatory or commercial steps.
Key Figures
Phase:Phase 3Genetic testing cohort:Over 400 individualsConference dates:May 9–12, 2026+4 more
Positive Phase 3 FORTIFY topline data for BBP-418 in LGMD2I/R9 with strong biomarker gains.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent clinical trial announcements have generally been positive and often accompanied by favorable stock reactions, with one notable divergence where positive interim data coincided with a negative move.
Recent Company History
This announcement continues BridgeBio’s pattern of highlighting late-stage data across its rare disease pipeline. Prior clinical updates included positive Phase 3 topline results for encaleret in ADH1 on Oct 29, 2025 and BBP-418 in LGMD2I/R9 on Oct 27, 2025, both with favorable safety and efficacy. Additional 2026 clinical news covered Phase 3 PROPEL 3 results in achondroplasia and FORTIFY interim data. Today’s CALIBRATE presentation at ECE fits into this sequence of maturing programs and external data disclosures.
Key Terms
autosomal dominant hypocalcemia type 1, adh1, non-surgical hypoparathyroidism, casr, +2 more
6 terms
autosomal dominant hypocalcemia type 1medical
"additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE"
A genetic disorder in which a commonly used calcium sensor in the body is overactive, causing chronically low blood calcium levels and symptoms like muscle cramps, tingling or fatigue. Because it is inherited in a dominant pattern, one altered copy of the gene can cause the condition. Investors should care because this straightforward biological cause creates a defined patient group for diagnostics, long‑term treatments, or drugs that modulate the calcium sensor, affecting market size and regulatory planning.
adh1medical
"Epidemiology and Clinical Management of ADH1: A Systematic Literature Review"
ADH1 is a gene that makes an enzyme called alcohol dehydrogenase 1, which helps the body break down alcohol and other small molecules. Investors see it in biotech or drug development news because changes in this enzyme can affect how a therapy works, who can safely take it, or whether a drug targets a metabolic pathway—think of it as a factory machine that can change product quality and safety, which matters for market value and regulatory review.
non-surgical hypoparathyroidismmedical
"Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-Function CASR"
A chronic condition where the body does not make enough parathyroid hormone, causing low blood calcium levels and symptoms like muscle cramps, tingling or fatigue; unlike the surgical form, it is not caused by neck surgery but by autoimmune, genetic or other non‑surgical causes. Investors should care because it creates long‑term demand for prescription therapies, monitoring tools and potential new treatments, affecting drug pipelines, market size and regulatory risk in the endocrine and rare‑disease sectors.
casrmedical
"Shows Gain-of-Function CASR Variants as the Most Common Genetic Cause Identified"
The calcium‑sensing receptor (CaSR) is a sensor protein on certain cell surfaces that detects and responds to the level of calcium in the blood, acting like a thermostat that tells the body to raise or lower calcium-related activity. It matters to investors because drugs that turn CaSR up or down can treat conditions such as abnormal parathyroid function, kidney stones, and bone disorders, so discoveries or approvals involving CaSR can change a company’s clinical prospects and market value.
phase 3medical
"from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
epostertechnical
"The Company will also share an additional oral presentation, one poster, and one eposter at the meeting."
An eposter is a digital version of a scientific poster used to present research results at conferences or online; it summarizes a study’s purpose, methods and key findings in graphics and short text. For investors, an eposter offers an early, accessible look at clinical or technical data that can affect expectations about a company’s prospects, but it is usually a condensed, not-yet peer-reviewed snapshot rather than a full, detailed report—think of it as a billboard summary versus the full technical white paper.
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting.
Oral Presentations: Encaleret Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE Trial Presenter: Filomena Cetani, M.D., Ph.D., University of Pisa, IT Date & Time: Tuesday, May 12 at 11:50 am CEST
Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-Function CASR Variants as the Most Common Genetic Cause Identified Presenter: Arun Mathew, BridgeBio Endocrinology, U.S. Date & Time: Tuesday, May 12 at 12:20 pm CEST
Poster: Autosomal Dominant Hypocalcemia Type 1 and Type 2: Baseline Quality of Life Measures in Adult Participants in the CLARIFY Disease Monitoring Study Presenter: Heide Siggelkow, M.D., University Medical Center of Göttingen, DE Poster ID: P72 Date & Time: Sunday, May 10 at 4:55 pm CEST and Monday, May 11 at 5 pm CEST
ePoster: Epidemiology and Clinical Management of ADH1: A Systematic Literature Review Presenter: Arun Mathew, BridgeBio Endocrinology, U.S. Poster ID: EP260
About BridgeBio BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact: Bubba Murarka, Executive Vice President contact@bridgebio.com (650)-789-8220
When and where will BridgeBio (BBIO) present CALIBRATE Phase 3 results for encaleret?
BridgeBio will present primary CALIBRATE Phase 3 results at ECE in Prague on May 12, 2026. According to the company, the oral presentation is scheduled for Tuesday, May 12 at 11:50 am CEST by Filomena Cetani, with an additional oral talk at 12:20 pm CEST.
What clinical topic does the CALIBRATE Phase 3 oral presentation address for BBIO (NASDAQ: BBIO)?
The oral presentation addresses encaleret restoring mineral homeostasis in ADH1 based on primary CALIBRATE results. According to the company, Filomena Cetani will present data on mineral homeostasis in autosomal dominant hypocalcemia type 1.
Which other BridgeBio presentations are scheduled at ECE 2026 besides the CALIBRATE oral talk?
BridgeBio will present an additional oral talk, one poster (P72) and one ePoster (EP260) at ECE 2026. According to the company, topics include genetic testing in non-surgical hypoparathyroidism and baseline quality-of-life measures in ADH studies.
Who are the presenters for BridgeBio’s ECE abstracts and what are their topics?
Presenters include Filomena Cetani, Arun Mathew and Heide Siggelkow covering encaleret efficacy, CASR variant genetic testing, and ADH baseline quality-of-life. According to the company, each presentation specifies presenter, topic, and scheduled time or poster ID.
What are the scheduled poster and ePoster details for BridgeBio at ECE 2026?
The poster (ID P72) on ADH1 and ADH2 baseline quality-of-life is scheduled May 10–11, and ePoster EP260 covers ADH1 epidemiology and management. According to the company, poster P72 shows Sunday May 10 at 4:55 pm CEST and Monday May 11 at 5 pm CEST.
Does BridgeBio say how many patients or datasets will be included in the ECE presentations?
The company notes genetic testing included over 400 individuals with non-surgical hypoparathyroidism in one presentation. According to the company, that oral presentation reports testing of over 400 individuals identifying gain-of-function CASR variants as common causes.
